LIRAGLUTIDE
DrugBank ID: db06655
DrugCentral: liraglutide
Synonymous :arg34lys26-(n-ε-(γ-glu(n-α-hexadecanoyl)))-glp-1[7-37] | liraglutida | liraglutide (genetical recombination) | liraglutide (rdna origin) | liraglutide recombinant | liraglutidum | n²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]glp-1-(7-37)-peptide | n²⁶-(n-hexadecanoyl-l-gamma-glutamyl)-[34-l-arginine]glucagon-like peptide 1-(7-37)-peptide
Drug Sentece Context
Table 1. Analysis of context sentence of liraglutide gene in 1 abstracts.
| pmid | sentence |
|---|---|
| 32900588 | The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin. |
| 33440950 | In this case, we described A 65-year-old male with hypertension and diabetes was diagnosed with severe COVID-19, he took liraglutide at doses ranging from 0.8 to 1.8 mg. […] Before admission, liraglutide was not used to reduce blood glucose. […] The case showed that liraglutide may be effective and safe used in patients with severe COVID-19 combined with type 2 diabetes, but more clinical trials are needed. |